Measuring impact of benign thyroid diseases on quality of life
Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Standard
Measuring impact of benign thyroid diseases on quality of life. / Watt, Torquil.
Encyclopedia of Endocrine Diseases. Elsevier, 2018. s. 802-812.Publikation: Bidrag til bog/antologi/rapport › Bidrag til bog/antologi › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - CHAP
T1 - Measuring impact of benign thyroid diseases on quality of life
AU - Watt, Torquil
N1 - Publisher Copyright: © 2019 Elsevier Inc.
PY - 2018
Y1 - 2018
N2 - Quality of life (QoL), defined as “the subjective assessment of the impact of disease and its treatment across the physical, psychological, social, and somatic domains of functioning and well-being,” is measured by patient-reported outcomes, abbreviated PRO. PROs may be generic or disease specific. This article focuses on the latter, by reviewing existing thyroid-specific QoL measures or “PROs.” Thirteen instruments were reviewed, characterized and had their measurement properties evaluated. Eight of these were developed in accordance with current standards: Three instruments for patients with Graves’ orbitopathy: Graves’ orbitopathy quality of life instrument (GO-QOL), Graves’ ophthalmopathy quality of life scale (GO-QLS) and Thyroid eye disease quality of life scale (TED-QOL) and one triplet of instruments for patients with hypothyroidism, Underactive thyroid-dependent quality of life questionnaire (ThyDQoL), Thyroid symptom rating questionnaire (ThySRQ) and Thyroid treatment satisfaction questionnaire (ThyTSQ) and Thyroid-related patient reported outcome (ThyPRO/ThyPRO-39 (short-form)), for patients with any benign thyroid disease, and thus the only PRO validated for use among patients with non-toxic goiter and hyperthyroidism.
AB - Quality of life (QoL), defined as “the subjective assessment of the impact of disease and its treatment across the physical, psychological, social, and somatic domains of functioning and well-being,” is measured by patient-reported outcomes, abbreviated PRO. PROs may be generic or disease specific. This article focuses on the latter, by reviewing existing thyroid-specific QoL measures or “PROs.” Thirteen instruments were reviewed, characterized and had their measurement properties evaluated. Eight of these were developed in accordance with current standards: Three instruments for patients with Graves’ orbitopathy: Graves’ orbitopathy quality of life instrument (GO-QOL), Graves’ ophthalmopathy quality of life scale (GO-QLS) and Thyroid eye disease quality of life scale (TED-QOL) and one triplet of instruments for patients with hypothyroidism, Underactive thyroid-dependent quality of life questionnaire (ThyDQoL), Thyroid symptom rating questionnaire (ThySRQ) and Thyroid treatment satisfaction questionnaire (ThyTSQ) and Thyroid-related patient reported outcome (ThyPRO/ThyPRO-39 (short-form)), for patients with any benign thyroid disease, and thus the only PRO validated for use among patients with non-toxic goiter and hyperthyroidism.
KW - Health-related quality of life
KW - Patient-reported outcomes
KW - Quality of life measurement
KW - Well-being
U2 - 10.1016/B978-0-12-801238-3.64960-7
DO - 10.1016/B978-0-12-801238-3.64960-7
M3 - Book chapter
AN - SCOPUS:85079264773
SN - 9780128121993
SP - 802
EP - 812
BT - Encyclopedia of Endocrine Diseases
PB - Elsevier
ER -
ID: 303679210